Connor, Clark & Lunn Investment Management Ltd. Eq Rx, Inc. Transaction History

Connor, Clark & Lunn Investment Management Ltd.

$18.8 Billion
Q3 2024

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 10, 2023	BUY	$1.61 - $1.96 $65,530 - $79,775	40,702 Added 9.35%	476,106 $885,000
Q1 2023 May 09, 2023	BUY	$1.8 - $2.83 $192,459 - $302,589	106,922 Added 32.55%	435,404 $844,000
Q4 2022 Feb 10, 2023	BUY	$2.05 - $5.5 $673,388 - $1.81 Million	328,482 New	328,482 $808,000

Others Institutions Holding EQRX

# of Institutions

Shares Held

67.8M

Call Options Held

Put Options Held

Ah Equity Partners Bio Iii, L.L.C. Menlo Park, CA

19.2M
Shares

$0
100.0% of portfolio
Ah Equity Partners Bio Ii, L.L.C. Menlo Park, CA

17.4M
Shares

$0
60.15% of portfolio
Arboretum Ventures, Inc.

13.9M
Shares

$0
63.96% of portfolio
Ah Equity Partners Lsv I, L.L.C. Menlo Park, CA

11.4M
Shares

$0
8.42% of portfolio
Ah Equity Partners Lsv Ii, L.L.C. Menlo Park, CA

5M
Shares

$0
11.61% of portfolio

View Full List

About EQRx, Inc.

Ticker EQRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 448,140,992
Description
EQRx, Inc., a pharmaceutical company, engages in developing medicines primarily for the treatment of oncology and immune-inflammatory diseases in the United States. The company's pre-registrational programs in Phase III clinical trial include Aumolertinib, an epidermal growth factor receptor (EGFR) inhibitor for the treatment of patients with EG...

More about EQRX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Connor, Clark & Lunn Investment Management Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Connor, Clark & Lunn Investment Management Ltd. with notifications on news.

Account